<DOC>
	<DOCNO>NCT00974090</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy MP-513 ( Teneligliptin ) combination Sulfonylurea patient type 2 Diabetes 12 week administration evaluate safety efficacy MP-513 combination Sulfonylurea extension treatment 52 week .</brief_summary>
	<brief_title>Efficacy Safety Study MP-513 Combination With Sulfonylurea Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<criteria>Patients 20 75 year old Patients dietary management take therapeutic exercise diabetes 12 week administration investigational drug Patients whose HbA1c 7.0 % 10.0 % Patients take Sulfonylurea diabetes 12 week administration investigational drug Patients administer diabetes therapeutic drug prohibit concomitant use within 12 week administration investigational drug Patients type 1 diabetes , diabetes mellitus cause pancreas impairment , secondary diabetes ( Cushing disease , acromegaly , etc ) Patients Class III/IV heart failure symptom accord NYHA functional classification Patients gastrointestinal disorder ( diarrhea , vomit ) Patients serious diabetic complication Patients excessive alcohol addict Patients severe hepatic disorder severe renal disorder Patients pregnant , lactating , probably pregnant patient , patient agree contraception</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>insulin resistance</keyword>
</DOC>